Is the revised International staging system for myeloma valid in a real world population?

Br J Haematol. 2018 Feb;180(3):451-454. doi: 10.1111/bjh.14341. Epub 2016 Oct 13.

Authors

Ieuan Walker¹, Alice Coady¹, Michael Neat^{2

3}, Darius Ladon⁴, Reuben Benjamin^{5

6}, Inas El-Najjar^{2

5}, Majid Kazmi^{2

5}, Steve Schey^{5

6}, Matthew Streetly^{2

5

6}

Affiliations

¹ Guy's King's and St Thomas' School of Medicine, King's College London, London, UK.
² Department of Haematology, Guy's and St Thomas' Hospital Trust, NHS, London, UK.
³ Department of Cancer Genetics, ViaPath, Guy's and St Thomas' Hospital Trust, NHS, London, UK.
⁴ Department of Cytogenetics, Viapath, Kings College Hospital, London, UK.
⁵ Kings Health Partners, London, UK.
⁶ Department of Haematology, King's College Hospital, London, UK.

PMID: 27734463
DOI: 10.1111/bjh.14341

No abstract available

Keywords: classifications; multiple myeloma; myeloma; prognostic factors; risk factors.

Publication types

Letter

MeSH terms

Humans
Multiple Myeloma / diagnosis*
Multiple Myeloma / etiology
Multiple Myeloma / mortality
Multiple Myeloma / pathology
Neoplasm Staging* / methods
Neoplasm Staging* / standards